Tag
A multicenter Chinese registry study demonstrates that direct oral anticoagulants are noninferior to warfarin in preventing 1-year symptomatic recurrent venous thromboembolism after cerebral venous thrombosis, with exploratory bleeding outc
Extended venous thromboembolism prophylaxis using once-daily subcutaneous enoxaparin post-pancreatectomy does not significantly reduce thrombotic events; higher BMI heightens risk, signaling a need for optimized, possibly weight-based dosin
This study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.
This review examines the development, efficacy, and safety of combined oral contraceptives (COCs), highlighting the emergence of natural-estrogen-containing formulations and their role in optimizing contraceptive care.
Over 25% of endometrial cancer patients receiving chemotherapy develop venous thromboembolism, with advanced cancer stage as the key risk factor, highlighting the need for tailored risk assessment and preventive strategies.
A quality improvement initiative integrating oral anticoagulants reduced venous thromboembolism incidence in ovarian cancer patients undergoing first-line chemotherapy without increasing bleeding risks.
A comprehensive Danish nationwide study reveals that women with endometriosis face a significantly increased long-term risk of venous thromboembolism, underscoring the need for heightened clinical vigilance and tailored risk management.
A nationwide French study reveals that nearly half of maternal deaths due to venous thromboembolism are preventable, emphasizing the importance of ongoing risk assessment and appropriate thromboprophylaxis during pregnancy and postpartum.
This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.
A nationwide Dutch study suggests pregnancy in women with peripheral vascular malformations is frequently complicated by symptom progression and postpartum hemorrhage, with venous thromboembolism concentrated in extensive lower-extremity ma
In a post hoc analysis of CLEAR Outcomes, bempedoic acid was associated with a significantly lower risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, among statin-intolerant patients at high cardiovascula
Routine oral rivaroxaban prophylaxis in ACTH-dependent Cushing syndrome was associated with no new VTE events after implementation and no bleeding complications, suggesting it is a safe and effective preventive strategy.
New research identifies P2Y14R as a key regulator of neutrophil-platelet aggregates and NET formation in venous thrombosis, with proglumide showing promise as a therapeutic antagonist.
Elevated levels of inflammatory and cardiac biomarkers are linked to higher risks of venous thromboembolism and bleeding in cancer patients, according to a post hoc analysis of the AVERT trial.
This review synthesizes findings from a landmark proteomic study identifying 23 plasma proteins associated with VTE risk, highlighting novel pathways in immunity and vascular senescence while exploring causal links through Mendelian Randomi
This large-scale proteomic analysis identifies 15 novel protein markers for venous thromboembolism, offering new insights into the roles of immunity and extracellular matrix regulation in VTE pathogenesis beyond traditional coagulation path
This review synthesizes cutting-edge findings from multi-ethnic longitudinal cohorts using high-throughput proteomics to identify novel biomarkers and causal pathways for venous thromboembolism, moving beyond traditional clotting factors.
A groundbreaking large-scale proteomic study identified 15 novel plasma markers for venous thromboembolism, highlighting biological pathways in extracellular matrix regulation and vascular senescence.
The ADJUST-DVT study confirms that an age-adjusted D-dimer cutoff (age × 10 µg/L) safely increases the number of patients in whom deep vein thrombosis can be ruled out without imaging, particularly benefiting patients over 75 years of age.
A large Dutch cohort study found that after adjusting for socioeconomic status and lifestyle, transgender women on oestradiol had lower myocardial infarction (MI) risk but higher venous thromboembolism (VTE) risk; transgender men on testost
